The AIM-listed biopharmaceutical company, Lipoxen Plc, has appointed Ajay K. Agrawal as head of business development. Dr Agrawal is currently a non-executive director and chairman of the remuneration and vice-chairman of the audit committees of ImmuPharma Plc. He will be replacing Peter Laing who is being promoted to the position of chief operating officer. Dr Laing joined Lipoxen in March 2002 having previously held executive positions at Actinova Ltd, Syngenix Ltd and Peptide Therapeutics, which is now Acambis Plc. He is currently non-executive chairman of Activotec Ltd.
Lipoxen is a 1997 spin-out of the School of Pharmacy at the University of London. It develops and commercialises early-stage protein, vaccine and anti-cancer drug candidates and takes them into clinical trials. It has strategic partnerships with a number of large biotechnology and pharmaceutical companies including Amgen, Genentech and Genzyme.
Copyright 2008 Evernow Publishing Ltd